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In renal transplantation, use of calcineurin inhibitors
(CNIs) is associated with nephrotoxicity and
immunosuppression with malignancies and infec-
tions. This trial aimed to minimize CNI exposure and
total immunosuppression while maintaining efficacy.
We performed a randomized controlled, open-label
multicenter trial with early cyclosporine A (CsA)
elimination. Patients started with basiliximab, pred-
nisolone (P), mycophenolate sodium (MPS), and CsA.
At 6 months, immunosuppression was tapered to
P/CsA, P/MPS, or P/everolimus (EVL). Primary out-
comes were renal fibrosis and inflammation. Second-
ary outcomes were estimated glomerular filtration
rate (eGFR) and incidence of rejection at 24 months.
The P/MPS arm was prematurely halted. The trial
continued with P/CsA (N = 89) and P/EVL (N = 96).
Interstitial fibrosis and inflammation were signifi-
cantly decreased and the eGFR was significantly
higher in the P/EVL arm. Cumulative rejection rates
were 13% (P/EVL) and 19% (P/CsA), (p = 0.08). A
post hoc analysis of HLA and donor-specific anti-
bodies at 1 year after transplantation revealed no
differences. An individualized immunosuppressive
strategy of early CNI elimination to dual therapy
with everolimus was associated with decreased allo-
graft fibrosis, preserved allograft function, and good
efficacy, but also with more serious adverse events
and discontinuation. This can be a valuable alterna-
tive regimen in patients suffering from CNI toxicity.
Abbreviations: AE, adverse events; AUC, area-under-
the concentration-over-time curve; CNI, calcineurin
inhibitors; CsA, cyclosporine; eGFR, estimated
glomerular filtration rate; EVL, everolimus; IF/TA,
interstitial fibrosis/tubular atrophy; MPS, mycopheno-
late sodium; mTOR, mammalian-target-of-rapamycin;
P, prednisolone; PSR, picro sirius red; SAE, serious
adverse events
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Introduction
Renal transplantation is the preferred treatment for
patients with end-stage renal failure. The optimal mainte-
nance immunosuppressive therapy after renal transplan-
tation remains to be defined. Premature death by
cardiovascular, malignant, and infectious causes is asso-
ciated with, and in part directly attributable, to the
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prolonged use of immunosuppressive drugs and their
cumulative load (1). In the last decade, several studies
have addressed the optimal strategy to minimize expo-
sure to calcineurin inhibitors (CNIs) (2–4). Apart from
their unfavorable cardiovascular risk profile, both CNIs
tacrolimus and cyclosporine are inherently nephrotoxic
and associated with premature graft loss (5). A recent
meta-analysis comprising 11 337 transplant recipients
showed that reduction of the CNI improves graft survival
(6). On the other hand, it has become evident that
under-immunosuppression with ongoing low-grade allo-
immunity may also contribute to chronic graft failure (7).
Therefore, substitution of a CNI by a nonnephrotoxic
mammalian-target-of-rapamycin (mTOR) inhibitor will only
preserve graft function when the allo-antibody response
is also effectively suppressed. Complete avoidance and
replacement of a CNI by everolimus (EVL) in de novo
transplant recipients is not justified, since this strategy
results in unacceptable high acute rejection rates even
with induction therapy (8). Both the CAESAR and the
SYMPHONY studies show that reduced CNI dosing, as
opposed to full-dose CNI, is equally efficacious in pre-
venting acute rejection but only marginally improves renal
function (9,10). The CONVERT and the ASCERTAIN stud-
ies were initiated to replace CNIs by a mTOR inhibitor
late (i.e. 3.2 and 5.6 years, respectively), after transplan-
tation (4,11). This strategy proved to be safe but again
only minor improvements in renal function were found,
predominantly in patients with still-preserved renal func-
tion. In contrast, in the ZEUS study, renal allograft recipi-
ents were converted from CNI to EVL at 4–5 months
after transplantation to a triple drug regimen with
mycophenolate and steroids. This study reported signifi-
cantly better renal function up to 5 years after CNI elimi-
nation with similar graft loss, mortality, and incidence of
serious adverse advents (SAEs) (12).
The objective of the present study was to minimize
exposure to CNI and the total amount of immunosup-
pression and to conserve renal allograft function by
switching to a non-nephrotoxic double drug regimen early
after transplantation, while maintaining efficacy. All
patients started with quadruple immunosuppressive
therapy with exposure-controlled cyclosporine A (CsA)
minimization. At 6 months, patients were assigned to
their allocated treatment consisting of dual therapy with
steroids and either CsA, mycophenolate sodium (MPS),
or EVL. Primary outcome of this study was the develop-
ment of renal allograft fibrosis 2 years after transplanta-
tion. Secondary outcomes were renal function, rejection
rates, and adverse events (AEs). We hypothesized that
exposure to reduced-dose CsA with mycophenolate and
basiliximab induction followed by early CsA elimination
and switch to double therapy with everolimus would be
associated with less intragraft fibrosis and inflammation
and better renal function, without increasing rejection
rates. Furthermore, we investigated whether mainte-
nance immunosuppression with EVL as compared to
cyclosporine was associated with a rise in donor-specific
HLA antibodies.
Methods
Study design and patient population
The study was approved by the local institutional review board. A detailed
description of the design of the study and randomization methods have
been published previously (13). A 24-month prospective, multicenter,
open-label randomized controlled trial was conducted in three university
hospitals in the Netherlands. Patients between the ages of 18 and
70 years receiving a first or second renal transplant from a deceased or
living donor were eligible. Main exclusion criteria were a HLA-identical
sibling donor, a third or fourth transplant, and current or historical panel
reactive antibodies of more than 50% and A-B-O incompatibility.
Immunosuppression during the first 6 months after transplantation con-
sisted of two doses of 20 mg of basiliximab intravenously (i.v.), adminis-
tered prior to transplantation and on day 4, Di-adreson-F 2 9 50 mg i.v.
during the first 48 h followed by oral prednisolone (P) 10 mg daily, MPS
2 9 720 mg from the first postoperative day, and CsA. Drug exposure of
CsA after transplantation was monitored by serial sampling and calcula-
tion of 12-h areas-under-the concentration-over-time curve (AUC12). Tar-
get values of AUC12 for CsA were 5400 lg*h/L for the first 6 weeks, and
thereafter 3250 lg*h/L. Scheduled biopsies were performed at 6 months
after transplantation. Patients without rejection in the 6-month scheduled
biopsy underwent balanced randomization (1:1:1) to one of the following
treatment arms: (1) CsA (target AUC12 3250 lg*h/L), (2) MPA (target
AUC12 40 mg*h/L) or a trough level >2 mg/L, or (3) EVL (target AUC12
150 lg*h/L). All patients continued on P 5–10 mg daily.
During the trial, the Data Monitoring Committee reviewed unblinded data
and concluded that the P/MPS group had a significantly higher incidence
of acute rejection after randomization and consequently this study arm
was halted and changes to the protocol were amended (13).
In this investigator-driven trial, there was no independent external moni-
toring. Monitoring of SAEs relied solely on the assessment of the investi-
gators. The trial was followed by an Independent Safety Monitoring
Board monitoring.
Concomitant therapy
Concomitant therapy consisted of a proton pump inhibitor, antihyperten-
sive medicines, and atorvastatin, when needed. Biopsy-proven rejection
was treated with methylprednisolone pulses. Refractory rejection epi-
sodes were treated with rabbit antithymocyte globulin (Pasteur Merieux,
Marnes-la-Coquette, France).
Therapeutic drug monitoring
AUC12s for CsA and EVL were calculated from blood samples drawn at C0,
1, 2, 3, 4, 5, and 6 h after administration. Pharmacokinetic monitoring and
clinical assessments were performed at week 2, and months 3, 6, 7, 12,
18, and 24. At week 6 or whenever indicated for clinical reasons, an AUC12
was calculated using only three blood samples drawn at 0, 2, and 3 h.
Protocol renal allograft biopsies
Protocol biopsies were scheduled at 6 and 24 months after transplantation.
Tissues were formalin-fixed and paraffin-embedded and stained with peri-
odic-acid Schiff diastase, hematoxylin/eosin, and Jones’ methenamine sil-
ver. Two independent renal pathologists (Leiden University Medical
Centre, Leiden and Academic Medical Centre, Amsterdam), unaware of
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any clinical data, classified the biopsies according to the latest update of
the Banff classification. Interobserver concordance for interstitial inflamma-
tion and interstitial fibrosis was good (Kendall W coefficient of concordance
0.68 and 0.80, respectively). The total percentage of inflamed cortical area
(ti-score), a continuous score as defined by Mengel et al (14), correlated
well between pathologists (Spearman q 0.66, p < 0.0001). Biopsies that
met the minimal adequacy threshold of seven glomeruli and one artery
were included for analysis. At 6 months, biopsies were obtained in 99%,
97%, and 98% of patients in the CsA MPS and EVL arm, respectively. Of
the available biopsies, 78%, 63%, and 81% in the CsA, MPS, and EVL arm
were considered adequate, respectively. At 24 months, biopsies were
obtained in 84% and 79% of patients in the CsA and EVL arm, respec-
tively. The prevalence of adequate samples was 81% and 73% in the CsA
and EVL arm, respectively (p = 0.4, two-tailed).
Morphometric analysis
The morphometric analysis of cortical interstitial fibrosis was centralized
at the AMC, Amsterdam. Adequate protocol biopsies were stained for
picro sirius red (PSR). PSR-stained slides were digitized using a slide vir-
tual microscope system (Olympus, Tokyo, Japan) using a 209 objective
and saved in TIFF format. Vessels that were larger than their adjacent
tubuli, glomeruli, the 0.5-mm subcortical area, and the medulla were
manually removed. Image analysis was performed with the ImageJ soft-
ware package (National Institutes of Health, Bethesda, MD). A macro
measured the PSR-stained area and the total tubulointerstitial area of the
biopsy. All input was manually verified.
Primary and secondary endpoints
The primary endpoints of the study were the development of interstitial
fibrosis at the 24-month protocol biopsy (morphometric analysis and
Banff interstitial fibrosis/tubular atrophy [IF/TA] score). Secondary end-
points of the study were the estimated glomerular filtration rate (eGFR;
estimated with the modification of diet in renal disease algorithm), the
incidence of acute rejection, and drug-related AEs (15). Diabetes was
defined as the need for antidiabetic drugs. In retrospect, generation of de
novo HLA class I and II donor-specific antibodies by Luminex assay at
12 months for those patients with available stored serum was addition-
ally determined.
Statistical analysis
Data from the MECANO trial were analyzed as an intention-to-treat esti-
mand. Differences in baseline parameters between the excluded and ran-
domized patients were calculated by independent sample t-tests and chi-
square tests where appropriate. In case of graft failure, an eGFR of
10 mL/min and the highest classified inflammation and fibrosis scores
were imputed. In the case of death, data were not imputed and were
considered missing. The difference in eGFR trajectories was analyzed by




- completed (n=0) 
- Not completed (n=39) 
- Change in regimen (n=9) 
- Regimen intolerability (n=2) 
- Consent withdrawn (n=2) 
- Graft loss (n=2) 
- Study discontinuation (n=25) 
Excluded (n=137) 
- Not meeting inclusion criteria(n=54) 
- Consent withdrawn (n=59) 
- Graft loss (n=16) 
- Deceased (n=7) 
- Other reasons (n=1) 
P/EVL (n=96) 
- completed (n=59) 
- Not completed (n=37) 
- Change in regimen (n=26) 
- Regimen intolerability (n=1) 
- Consent withdrawn (n=7) 
- Deceased (n=4) 
P/CsA (n=89) 
- completed (n=74) 
- Not completed (n=15) 
- Change in regimen (n=6) 
- Regimen intolerability (n=1) 
- Consent withdrawn (n=4) 
- Graft loss (n=3) 
- Deceased (n=1) 
24-months Banff (n=89) 
- completed (n=60) 
- Not completed (n=29) 
- Graft loss (n=3) 
- Deceased (n=1) 
- Not biposied (n=11) 
- Inadequate biopsy (n=14) 
24-months Banff (n=96) 
- completed (n=57) 
- Not completed (n=39) 
- Deceased (n=4) 
- Not biposied (n=16) 
- Inadequate biopsy (n=19) 
24-months morphometric analysis 
(n=89) 
- completed (n=59) 
- Material insufficient (n=1) 
24-months morphometric analysis 
(n=57) 
- completed (n=55) 
- Material insufficient (n=2) 
Study arm halted
Figure 1: Flow chart of the enrolled patients. P, prednisolone; MPS, mycophenolate sodium; CsA, cyclosporine; EVL, everolimus.
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rejection was compared between treatment groups in a time-to-event
structure with a log-rank test. Differences in ordinal data (i.e. Banff scores)
were calculated with Mann–Whitney ranks tests. Differences in continu-
ous parameters were calculated with use of independent sample t-tests.
Differences in de novo donor-specific antibodies (DSA) were calculated by
chi-square tests. A two-sided p-value of 0.05 was used as a significance
threshold. Data were analyzed in the R computational environment ver-
sion 2.15.2 for Macintosh (www.r-project.org). Prior to the study, the fol-
lowing power analysis was performed based on data of the quantitative
morphometric analysis that were acquired in our previous study (16). We
showed that 6 months after renal transplantation, the incidence of graft
fibrosis was 12%. We assumed that after 24 months the incidence of
graft fibrosis in the cyclosporine-treated patients would be 40% and 30%
in the two other intervention arms. In order to have a power of 0.80 and
an alpha of 0.05, we needed 70 patients per treatment group, taking into
account that at 24 months, 85% of patients would reach the primary end-
point. Since there was a high correlation between the co-primary end-
points, (i.e. fibrosis by morphometric analysis and by the Banff score),
adjustment of the p-value by for multiple testing was not necessary (17).
Results
Randomization and baseline characteristics
From November 2005 to June 2009, a total of 361 patients
were enrolled (Figure 1). Of these patients, 85 ended the
study before the 6-month protocol biopsy mainly due to the
intensity of the study protocol. Two hundred seventy-five
patients underwent a scheduled biopsy. Fifty of these
patients showed a Banff type borderline or 1A rejection in
this biopsy, whereas in three others Banff class 1b or more
was noted. Another three patients were not further tapered
to their allocated regimen due to their specific need for an
immunosuppressive regimen other than the assigned treat-
ment. In five patients the immunosuppressive therapy was
mistakenly tapered. Of the 89 patients assigned to P/CsA,
73 were still on the trial medication at the end of the study
versus 58 of 96 patients in the P/EVL group (p = 0.0012,
chi-square). On recommendation by the data safety moni-
toring board, the P/MPS arm was prematurely halted after
enrollment of 39 patients due to a significantly higher num-
ber of acute rejections (13). The trial continued as a two-
arm trial comparing P/EVL with P/CsA. Baseline characteris-
tics of the randomized patients are depicted in Table 1.
Table S1 shows the characteristics of the randomized
patients compared to the excluded patients. Table S2
shows the primary outcomes in all enrolled patients. Fol-
low-up in groups 1 and 3 was 730 (2–730) and 730 (6–730)
days (median [minimum–maximum]).
Therapeutic drug monitoring
Mean CsA AUC12 hrs at 6 months was 3280  971 lg*h/L.
There were no significant differences between patient
groups. At 24 months, mean CsA AUC12 hrs was 3278 
907 lg*h/L. Drug exposure to EVL was 203  21 lg*h/L
1 month after conversion and 159  44 lg*h/L at
24 months.
Longitudinal data showing trough levels and daily doses
are listed in Table 2.
Graft fibrosis
Interstitial fibrosis at 24 months as measured by PSR
staining was lower in the P/EVL group compared to the
P/CsA group (mean difference 6%, 95% CI 3–10%,
p = 0.001) (Table 3). Delta6–24 interstitial fibrosis percent-
age was lower in the P/EVL as well (mean difference
6%, 95% CI 1–10%, p = 0.01). The 24-month IF/TA
score was lower in the P/EVL group (W = 2143.5,
p = 0.03) as was the delta6–24 IF/TA score (W = 1465,
p = 0.1) (Table 3). There was a trend towards a lower
arteriolar hyalinosis and transplant glomerulopathy score
at 24 months in the P/EVL versus the P/CsA group (all
p ≤ 0.1, Table 3). The percentage of sclerosed glomeruli
and the transplant vasculopathy score did not differ
between groups.
Clinical and subclinical rejection
Total inflammation at 24 months as well as its delta6–24
value was lower in the P/EVL group compared to P/
CsA (mean difference at 24 months 14% [95% CI
Table 1: Baseline characteristics of the randomized patients
P/CsA P/EVL
Recipient (N) 89 96
Age (years) 49  13 51  13
Male sex (%) 63 65







Cause of end-stage renal disease (%)
Glomerulonephritis 19 18
Diabetes mellitus 2 4
Pyelonephritis or interstitial nephritis 3 3
Focal segmental glomerulosclerosis 3 4
Urologic 6 10





Type of donor (%)
Post mortal—heart-beating 26 29
Post mortal—non-heart-beating 15 19
Living related 26 22
Living unrelated 34 30
Donor age (years) 49  14 49  13
Donor male sex (%) 53 61
Antigen mismatches—A, B,
and DR (no.)
3  2 3  2
Cold-ischemia time—deceased
donors only (h)
17  5 16  5
Delayed graft function (%) 12 16
First transplants (%) 96 94
Plus–minus values are means  standard deviation.
P, prednisolone; CsA, cyclosporine; EVL, everolimus.
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3–24%] and delta6–24 13% [95% CI 3–23%], both
p = 0.01, Table 3). At the 24-month protocol biopsy,
the prevalence of subclinical rejection-free patients did
not differ between the treatment arms (83% vs. 82%,
respectively). Banff g, t, and i scores were not signifi-
cantly different between groups (Table 3). Arteritis was
not present in any of the protocol biopsies. After ran-
domization, at 24 months the cumulative incidence of
acute clinical rejection in the P/CsA group was 9% as
compared to 3% in the P/EVL group (Figure 2A,
p = 0.08).
Generation of de novo donor-specific antibodies
after randomization
Of the patients who finalized the study protocol, 26/69
(38%) patients in the P/CsA and 16/54 (30%) in the P/
EVL group developed de novo anti-HLA class I or II anti-
bodies (p = 0.35), of which 12/69 (17%) and 5/54 (10%)
were DSA, respectively (p = 0.195). No significant differ-
ences in de novo class I and II DSA were observed
(p = 0.12 for class I and p = 0.81 for class II).
Patient survival, graft survival, and graft function
After randomization, overall graft survival was 96% in the
P/CsA as well as P/EVL group. Patient survival in the P/
CsA group was 99% and in the P/EVL group 96%. In the
P/CsA group, death-censored graft survival was 97%
compared to 100% in the P/EVL group. The eGFR trajec-
tory in the P/EVL arm was higher at each time-point after
randomization as compared to the eGFR trajectory in the
P/CsA arm (Figure 2B, p < 0.05, linear mixed-effects
model).
Proteinuria and total cholesterol levels at months 6
and 24
Proteinuria (g/24 h) at months 6 and 24 after transplanta-
tion was 0.24 (interquartile range [IQR] 0.15–0.36) and
0.20 (IQR 0.13–0.30) in the P/CsA group and 0.22 (IQR
0.14–0.30) and 0.30 (IQR 0.18–0.49) in the P/EVL group
(median [IQR]). This was not significant (p = 0.21)
(Mann–Whitney rank test).
Cholesterol levels at months 6 and 24 after transplanta-
tion are shown in Table 4.
Adverse events
AEs and SAEs are depicted in Table 5. There were signifi-
cantly more SAEs in the P/EVL group as compared to the
P/CsA group after effective allocation to treatment
(p < 0.001, chi-square). In the P/CsA group, one patient
died due to myocardial infarction. In the P/EVL group, four
patients died: two by “sudden death,” one after a stroke,
Table 2: Daily immunosuppressive doses, trough levels, and C2 levels (CsA)
P/CsA (N = 89) P/EVL (N = 96)
Mean  SD Median (min–max) Mean  SD Median (min–max)
Month 6 (N = 89) (N = 96)
CsA daily dose (mg) 229  58 200 (100–400) 222  57 200 (100–400)
CsA Ctrough (lg/L) 122  51 110 (33–333) 117  41 113 (25–219)
MPS daily dose 1395  171 1440 (720–1440) 1395  176 1440 (720–1440)
MPA Ctrough (mg/L) 3  3.5 2.1 (0.6–28.5) 3.2  3.6 2.3 (0.5–19.5)
P dose 10  1.0 10 (8–10) 10  1.0 10 (8–10)
Month 7 (N = 89) (N = 96)
CsA daily dose 226  32 200 (150–350)
CsA Ctrough (lg/L) 132  61 119 (30–453)
CsA C2 (lg/L) 653  207 654 (260–1163)
EVL daily dose 5.92  0.4 6 (3–9)
EVL Ctrough (lg/L) 10.7  5.8 9.1 (4.2–32.2)
P dose 10  1.0 10 (8–15) 10  0.8 10 (5–10)
Month 12 (N = 77) (N = 81)
CsA daily dose 224  54 200 (100–350)
CsA Ctrough (lg/L) 121  46 112 (33–300)
CsA C2 (lg/L) 653  207 654 (260–1163)
EVL daily dose 4.8  0.8 4.5 (2–10.5)
EVL Ctrough (lg/L) 9.3  3.6 8.7 (3.8–23.2)
P dose 10  2.0 10 (5–25) 10.5  5 10 (8–50)
Month 24 (N = 70) (N = 59)
CsA daily dose 218  58 200 (100–400)
CsA Ctrough (lg/L) 123  72 108 (17–469)
CsA C2 (lg/L) 656  224 628 (130–1389)
EVL daily dose 4.2  0.7 4.5 (1.5–7.5)
EVL Ctrough (lg/L) 8.9  3.1 8.1 (3.3–16.2)
P dose 10  1.0 10 (8–10) 10  1 10 (5–10)
CsA, cyclosporine; MPS, mycophenolate sodium; MPA, mycophenolic acid; P, prednisolone; EVL, everolimus; SD, standard deviation.
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and one due to carcinoma of the lung. Twenty-six patients
in the EVL arm changed their immunosuppressive mainte-
nance regimen. Reasons to switch to a different immuno-
suppressive regimen other than P/EVL were rejection (3),
pneumonitis (10), severe rash (4), edema (2), diarrhea (2),
severe malaise (2), pulmonary embolism (1), severe hyper-
triglyceridemia (1), and BK nephropathy (1).
Discussion
This study is the first prospective study with early com-
plete CsA withdrawal and conversion to dual therapy
consisting of prednisolone and everolimus with as pri-
mary outcome a quantitative histopathological analysis of
fibrosis in scheduled renal transplant biopsies. This mor-
phometric outcome is a good surrogate marker for long-
term allograft function and eGFR (18). The study has two
other distinct features: (1) prior to effective allocation to
the various weaning regimens, scheduled biopsies were
analyzed to rule out subclinical rejection, and (2) immuno-
suppressive drug monitoring was tightly controlled using
AUCs instead of trough levels. This study shows that
controlled reduced CsA exposure with mycophenolate
followed by early CsA withdrawal and dual maintenance
therapy with steroids and everolimus is associated with
less fibrosis and decreased inflammation as compared to
dual therapy with steroids and CsA. Both chronic histo-
logical damage and the total inflammation score are
important predictors of renal allograft outcome (14,19).
Histological lesions such as interstitial fibrosis, tubular
atrophy, and arteriolar hyalinosis are associated with CNI
toxicity but also occur in renal allograft recipients not on
CNIs (20). Enhanced allo-immunity is assumed to be a sec-
ond important risk factor for the development of these
lesions (21). In this study, everolimus proved to be very
efficacious, and significantly better than MPS, to suppress
the allo-response, provided that, prior to withdrawal, drug
levels were adequate and subclinical rejection was
excluded. The previously reported differences in efficacy
between CNIs and mTOR inhibitors (8) are in contrast with
our study, but can be explained by the controlled drug
exposure and/or the absence of drug–drug interactions
(22). In the present trial, exposure to CsA and EVL were
controlled using AUC12 h instead of trough levels. CsA
trough levels especially have been shown to correlate
poorly with systemic exposure and clinical outcome
parameters (23). Our data are in concordance with those
of Chhabra et al, who demonstrated in a randomized sin-
gle-center study that tacrolimus replacement by sirolimus
in a dual maintenance regimen with MPA was equally effi-
cacious as the control arm that continued on tacrolimus.
However, in the latter study no beneficial effect on either
graft histology or on clinical parameters was reported, pos-
sibly due to the late time point of conversion (24). A sec-
ond explanation of the better histological outcome in the
everolimus arm may be intrinsic antifibrotic properties
ascribed to mTOR inhibitors (25).
The histological data of the study are in line with the
renal allograft function. The mean eGFR at 2 years after
Table 3: Quantitative histological analysis of the protocol biop-




At 6 months 0 (0–0), 21% 0 (0–0), 14%
At 24 months 0 (0–1), 35% 0 (0–1), 32% 0.61
Delta6–24 0 (0–0.5), 25% 0 (0–0.75), 26% 0.9
1
i-score
At 6 months 1 (0–1), 57% 1 (0–1), 57%
At 24 months 1 (0–1.5), 71% 1 (0–2), 66% 0.71
Delta6–24 0 (0–1), 40% 0 (0–1), 35% 0.8
1
g-score
At 6 months 0 (0–0), 1% 0 (0–0), 3%
At 24 months 0 (0–0), 16% 0 (0–0), 7% 0.11
Delta6–24 0 (0–0), 13% 0 (0–0), 7% 0.3
1
ti-score, %
At 6 months 11  8 13  11
At 24 months 37  33 24  23 0.012
Delta6–24 24  30 11  20 0.012
Graft fibrosis
IF/TA-score
At 6 months 1 (0–1), 69% 1 (0–1), 66%
At 24 months3 1 (1–2), 92% 1 (1–2), 88% 0.031
Delta6–24 1 (0–1), 56% 0 (0–1), 43% 0.1
1
cg-score
At 6 months 0 (0–0), 1% 0 (0–0), 1%
At 24 months 0 (0–0), 8% 0 (0–0), 2% 0.11
Delta6–24 0 (0–0), 5% 0 (0–0), 2% 0.2
1
cv-score
At 6 months 0 (0–1), 31% 0 (0–1), 33%
At 24 months 0 (0–1), 46% 0 (0–1), 45% >0.91
Delta6–24 0 (0–1), 36% 0 (0–1), 43% 0.6
1
ah-score
At 6 months 0 (0–0), 24% 0 (0–1), 37%
At 24 months 0 (0–1), 46% 0 (0–1), 36% 0.11
Delta6–24 0 (0–1), 29% 0 (0–0), 24% 0.3
1
GGS, %
At 6 months 3  5 3  5
At 24 months 9  12 6  8 0.22
Delta6–24 5  13 3  11 0.52
IF, %
At 6 months 13  6 14  6
At 24 months 21  12 15  8 0.0012
Delta6–24 7  13 1  8 0.012
Ordinal Banff scores are depicted as median (interquartile
range), percentage of patients with a score >0. The ti-score, the
percentage of GGS, and the percentage of IF are shown as
mean  standard deviation. The percentage represents the frac-
tion of the cortex with fibrosis. Banff v-score values were 0 in
all protocol biopsies and therefore not shown.
GGS, global glomerulosclerosis; IF, interstitial fibrosis (morpho-
metric analysis of picro-sirius red staining); TA, tubular atrophy.
1Two-sided Mann–Whitney rank test.
2Two-sided t-test.
3The percentage of patients with IF/TA score >1 at 24 months
was 46% in the P/CsA group versus 29% in the P/EVL group.
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Figure 2: Clinical renal outcome from the P/EVL and P/CsA groups. Rejection-free survival from t = 0 (A) and t = 6 months (B)
and eGFR trajectories (C) and delta eGFR trajectories (D). P, prednisolone; EVL, everolimus; CsA, cyclosporine; eGFR, estimated
glomerular filtration rate.
Table 4: Cholesterol and proteinuria levels at month 6 and month 24
Time
P/CsA (n = 89) P/EVL (n = 96)
pN Mean SD N Mean SD
Cholesterol (mmol/L) Month 6 87 5.22 1.04 96 5.18 1.01 n/a
Month 24 80 5.12 0.98 89 5.40 1.13 0.0881
Proteinuria g/24 h Month 6 86 0.23 0.15–0.36 95 0.22 0.14–0.30 n/a
Month 24 82 0.20 0.13–0.30 88 0.30 0.18–0.48 0.2092
Proteinuria >0.5 (g/24 h) Month 24 12/82 14.6% 19/88 21.6% 0.2403
Statin use Month 6 52/87 59.8% 54/96 56.3% n/a
Month 24 53/77 68.8% 51/72 70.8% 0.2393
Proteinuria g/24 h are presented as median (IQR).
P, prednisolone; CsA, cyclosporine; EVL, everolimus; SD, standard deviation; n/a, not applicable.
1Tested with independent samples t-test.
2Tested with Mann–Whitney rank test.
3Tested with Pearson chi-square.
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AE SAE AE SAE
P/CsA P/EVL P/CsA P/EVL P/CsA P/EVL P/CsA P/EVL
Total episodes 59 77 26 22 40 61 32 71
Total patients with episode 35 (39%) 44 (46%) 18 (20%) 12 (13%) 36 (40%) 43 (45%) 19 (21%) 44 (46%)
p = 0.12 p = 0.12 p = 0.68 p < 0.01
Gastrointestinal—total 0 2 2 1 2 2 4 7
Gingiva hyperplasia 0 0 0 0 1 0 0 0
Diarrhea 0 2 1 1 1 2 3 7
Other gastrointestinal event 0 0 1 0 0 0 1
Urinary tract complications—total 35 26 12 8 14 19 6 12
Urinary tract infection 33 26 4 2 6 18 4 4
Urosepsis 1 0 5 4 5 0 0 8
Urological other 1 0 3 2 3 1 2 0
Respiratory—total 0 2 2 2 0 5 2 11
Pneumonia
Bacterial 0 2 2 0 0 3 2 0
PCP 0 0 0 2 0 0 0 2
Probably medication—related 0 0 0 0 0 2 0 9
Other infections—total 15 29 6 3 12 9 7 5
CMV
Primo 0 3 2 0 0 0 2 0
Reactivation 7 15 1 1 7 0 1 1
Herpes zoster 2 1 0 0 2 1 0 0
Herpes labialis 0 3 0 0 0 1 0 0
Infection other 6 7 3 2 3 7 4 4
Malignancies—total 0 0 1 1 0 0 3 3
Skin 0 0 0 0 0 0 2 1
Nonskin 0 0 1 1 0 0 1 2
Cardiovascular—total 4 3 1 3 2 2 5 12
Infarction 1 0 0 0 0 0 1 1
Venous thrombosis 1 1 1 1 0 1 0 7
Lung embolus 0 0 0 0 0 0 0 2
Peripheral arterial disease 1 0 0 0 0 0 1 1
Other cardiovascular event 1 2 0 2 2 1 3 1
New-onset diabetes mellitus 2 3 0 0 4 14 0 0
Gout 1 0 0 0 1 0 0 0
Flulike symptoms 1 2 0 0 1 0 5 0
Edema 0 4 1 0 1 2 0 0
Other 1 6 1 4 3 8 0 21
Death n/a n/a n/a n/a 0 0 1 4
SAE < 6 months: P/CSA gastrointestinal other: abdominal ileus, urological other: urethrotomy, acute urinary retention, hydronephrosis.
Infection other: peritoneal catheter–related peritonitis (2), bacteremia with Staphylococcus aureus, Other transient rise in creatinine. P/
EVL urological other; Hydronephrosis, replacement of by Boari splint, Infection other; fever of unknown cause, Escherichia coli bac-
teremia, Other: ablation of the retina, shortness of breath, acute tubulus necrosis, cognitive impairment. AE <6 months. P/CsA Urolog-
ical other; hydronephrosis, Infection other: perianal abscess (2), culture-positive preservation fluid, wound infection, peritonitis,
infected liver cyst. Other; tendinitis P/EVL Pos PCR EBV (2), wound infection, BK virus nephropathy, exacerbation chronic hepatitis B,
infected preservation fluid, oral candida Other; drug hepatitis, leucopenia, acute tubulus necrosis (3), rhinitis. SAE > 6 months P/CsA
Other Urological urethra stricture, lymphocele, Infection other infected renal cyst, abdominal wall, abscess (2), fever of unknown ori-
gin, Other cardiovascular; femoral bypass, subdural hematoma, arterial percutaneous angioplasty P/EVL Other Infection; fever of
unknown origin, BK nephropathy, infected renal cyst, colitis, Cardiovascular Other: angioplasty of shunt. Other: Eyelid correction, catar-
act (3), ablation of the retina, shunt problems (2), pain thorax wall, melena, angioedema, rise in creatinine (2), malaise (2), stenosis in
the spine, nephrectomy native kidney, skin rash (4), hypertriglyceridemia. AE >6 months P/CsA Other infection otitis media (2), upper
respiratory infection. Cardiovascular Other; shunt thrombosis, Other arthrosis, gingiva hyperplasia, bleeding from the gastrointestinal
tract, vaginal bleeding P/EVL Urological other; dysuria, Infection other; candida infection (3), bronchitis (2), abscess groin, fever of
unknown origin, Other; ulcers in mouth, shortness of breath (2), dyspepsia, skin rash, malaise, fracture tibia, luxation of the scapula.
P, prednisolone; CsA, cyclosporine; EVL, everolimus; PCP, Pneumocystis pneumonia; CMV, cytomegalovirus; PCR, polymerase chain
reaction; EBV, Epstein–Barr virus; n/a, not applicable.
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transplantation in the current study was 7 mL/min higher
in the EVL group as compared to patients in the CsA
group. The patients on CsA have a slow but progressive
decline in their eGFR, which is not observed in the EVL
arm.
We included patients with a standard-to-intermediate
immunological risk profile. The overall HLA matching rate
is relatively poor due to high numbers of living unrelated
donors. Protocol biopsies at 6 months were performed
to reduce the immunological risk, since patients with
inflammation in their surveillance biopsies did not pro-
ceed to their assigned dual treatment arm. After tapering
the triple regimen to double therapy, the 2-year cumula-
tive rejection incidences were 9% in the P/CsA group
and only 3% in the P/EVL group. In contrast, in the ZEUS
study patients converted to EVL experienced a higher
rejection rate as compared to those who continued on
triple therapy with cyclosporine. The difference may be
explained by the approach in therapeutic drug monitoring
or due to the fact that in the ZEUS study no preconver-
sion biopsies were performed to exclude subclinical
rejection. The results in the current study are more strik-
ing because in the ZEUS study, CsA elimination with
EVL was performed in the presence of mycophenolate.
We performed a post hoc analysis of the de novo inci-
dence of HLA antibodies and DSAs at 1 year after trans-
plantation. In a single-center study, the CNI-free regimen
was associated with an increased incidence of DSAs (26).
However, in this study a large part of the patients did not
use prednisolone, which might have resulted in underim-
munosuppression. We and others did not find such an
increase in DSAs in the EVL-treated patients (27).
Tolerability was significantly lower in the P/EVL group. At
2 years, only 60% of the patients were still on the
assigned treatment as compared to 88% of the P/CsA
patients. This is compatible with data from the literature
(28). Like others, we did not find a significant correlation
between the level of EVL exposure and side effects.
We did not find a difference between cardiovascular
events between the two groups nor in cholesterol levels.
In our analysis, cholesterol levels at 24 months were not
significantly increased as compared to levels at effective
randomization or between the two groups. However,
most patients needed statins to control their cholesterol
levels. EVL is associated with a dose-dependent
increased risk of hypercholesterolemia (29). This has
raised concern about the effect on cardiovascular events.
A recent observational cohort study comprising 9353
adult kidney transplant recipients with a median follow-
up of 7 years showed a higher risk of all-cause mortality
with mTOR use, as compared to CNI use. This risk, how-
ever, was largely explained by the increased risk of death
by malignancy, suggestive of an indication bias. In this
study, death by cardiovascular causes was not
independently increased; however, results should be
interpreted with caution since numbers in this subgroup
analysis were small (30).
On the other hand, mTOR inhibitors possibly have cardio-
protective effects; in a recent trial in 721 de novo heart
transplant patients randomized either to EVL and
reduced-dose CsA or CsA and mycophenolate mofetil, a
subanalysis of 185 patients showed significantly less inti-
mal thickness of the coronary arteries in the EVL-treated
patients. This was independent of cholesterol levels (31).
There are several limitations to the current study that
should be considered. First, we used CsA as the com-
parator drug and not tacrolimus. Whether the eGFR in a
P/tacrolimus arm would have been better is speculative.
In the 3-year follow-up of the SYMPHONY study, the
eGFR was only slightly better in the tacrolimus arm as
compared to the standard-dose CsA arm, but not in com-
parison to the reduced-dose CsA (24). Secondly, in our
study a comparator arm with a triple-drug calcineurin-
based immunosuppressive regimen is lacking. After MPS
withdrawal, an additional 9% of the CsA experienced an
acute rejection. However, survival without (borderline)
rejection for the CsA and EVL treatment arms was 83%
and 82%, respectively. For this selected group of
patients, with no signs of subclinical rejection in the 6-
month scheduled biopsy, the borderline-free rejection
survival was similar to the 1-year outcome of the best
arm in the Symphony trial. In this trial, borderline-free
rejection survival was 85% in the Low-Tac arm (32).
Thirdly, most of our patients were from a white back-
ground and, although based on controlled systemic expo-
sure, we cannot extrapolate our findings to other ethnic
groups. Fourthly, our AUC of EVL were relatively high
(target AUC12 150 lg*h/L), which is compatible with tar-
get trough levels of 8–12 lg/L. Finally, our follow-up was
only 2 years.
In conclusion, this trial included de novo renal transplant
recipients with a standard-to-intermediate immunological
risk. The results show that after exclusion of subclinical
rejection at 6 months, quadruple therapy followed by CsA
elimination with EVL in dual therapy with prednisolone is
safe, slows the progression of interstitial fibrosis and
inflammation, and preserves renal allograft function. Fur-
thermore, there were no differences between the groups
in the incidence of de novo HLA antibodies.
In a low-immunological risk group of patients, double
therapy with prednisolone and EVL can be a good alter-
native to a CNI-containing regimen.
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